Advertisement

Korreliert die Prävalenz der bisphosphonatassoziierten Kiefernekrosen mit der Einnahmedauer der Bisphosphonate bei Tumor- und Osteoporosepatienten?

Gesamtauswertung des Deutschen Kieferosteonekroseregisters

Correlating the prevalence of bisphosphonate-associated osteonecrosis of the jaw with the duration of onset of bisphosphonates in tumor and osteoporosis patients

Overall evaluation of the German osteonecrosis of the jaw registry

  • 3 Accesses

Zusammenfassung

Die erste Veröffentlichung zum Thema der Osteonekrose des Kieferknochens (ONJ, „osteonecrosis of the jaw“) erfolgte 2003. Bei Tumor- und Osteoporosepatienten werden im Zuge ihrer Grunderkrankung Bisphosphonate appliziert. Dies geschieht bei Tumorpatienten zur Risikoreduktion der Entwicklung einer Knochenmetastasierung, bei Osteoporosepatienten zur Verringerung des Frakturrisikos. Trotz der geringen Wahrscheinlichkeit werden Nebenwirkungen in Form von Nekrosen nach Interventionen am Kieferknochen häufig von den behandelnden Ärzten erwartet. Nach Auswertung der Registerdaten konnte nicht festgestellt werden, dass die Länge der Einnahme mit der Prävalenz von ONJ korreliert. Die Lokalisationen der ONJ decken sich weitestgehend mit den Ergebnissen bisheriger Studien.

Abstract

The first description of osteonecrosis of the jaw (ONJ) was published in 2003. Bisphosphonates (BPs) have been used as antiresorptive agents to treat patients with osteoporosis or metastatic bone cancer. In patients with tumors and osteoporosis, bisphosphonates are applied as part of their underlying disease. Bisphosphonates are used in tumor patients to reduce the risk of developing bone metastases and in osteoporotic patients to reduce fracture risk. Despite the low likelihood, side effects in the form of necrosis after interventions on the jawbone are often expected by the treating physicians. After evaluating the registry data, it could not be determined that the length of intake correlated with the prevalence of ONJ. The localizations of the ONJ coincide with the results of recent studies.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6
Abb. 7
Abb. 8
Abb. 9
Abb. 10
Abb. 11
Abb. 12
Abb. 13
Abb. 14
Abb. 15
Abb. 16
Abb. 17
Abb. 18

Literatur

Verwendete Literatur

  1. 1.

    Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117

  2. 2.

    Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534

  3. 3.

    Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ) (2004) Osteonekrose des Kiefers unter Bisphosphonaten. Dtsch Arztebl 101:A2203

  4. 4.

    Freyschmidt J (1980) Knochenerkrankungen im Erwachsenenalter. Springer, Berlin

  5. 5.

    Akintoye SO, Lam T, Shi S et al (2006) Skeletal sitespecific characterization of orofacial and iliac crest human bone marrow stromal cells in same individuals. Bone 38:758–768

  6. 6.

    Stefanik D, Sann J, Lam T et al (2008) Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis 14:465–471

  7. 7.

    Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D’Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P (2006) Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 77(2):109–117

  8. 8.

    Re M, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575

  9. 9.

    Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97(12):2692–2696

  10. 10.

    Roelofs AJ, Thompson K, Gordon S, Rogers MJ (2006) Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 12:6222–6230

  11. 11.

    Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42:848–860

  12. 12.

    Bartl R, von Tresckow E, Bartl C (2006) Bisphosphonat Manual. Springer, Berlin, Heidelberg, New York, S 43–93. ISBN 3‑540-25362‑9

  13. 13.

    Yamaguchi A, Kubo S, Matsunaga T, Shibahara T (2018) Report by the jaw bone disease project 1: concept, diagnosis and treatment of medication-related osteonecrosis of the jaw. Shikwa Gakuho 118:165–176

  14. 14.

    Fleisch H (2002) The role of bisphosphonates in breast cancer: development of bisphosphonates. Breast Cancer Res 4(1):30–34

  15. 15.

    Mutschler E, Geisslinger G, Kroemer HK, Schäfer-Korting M (2001) Mutschler Arnzeimittelwirkungen, 8. Aufl. Wissenschaftliche Vertragsgesellschaft, Stuttgart, S 395–398

  16. 16.

    International Task Force on Osteonecrosis of the Jaw (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:1

  17. 17.

    Aspenberg P (2006) Osteonecrosis: what does ist mean? One condition partly caused by bisphosphonates—or another one, preferably treated with them? Acta Orthop 77(5):693–694

  18. 18.

    Allen MR, Ruggiero SL (2009) Higher bone matrix density exists in only subset of patients with bisphosphonate-related osteonecrosis of the jaw. J Oral Maxillofac Surg 67:1373–1377

  19. 19.

    Sharma D, Ivanovski S, Slevin M et al (2013) Bisphosphonate-related osteonecrosis of the jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect. Vasc Cell 5:1–5

  20. 20.

    Fedele S, Porter SR, D’Aiuto F et al (2010) Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123:1060–1064

  21. 21.

    Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433–441

  22. 22.

    Fournier P, Boissier S, Filleur S et al (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544

  23. 23.

    Santini D, Vincenzi B, Dicuonzo G et al (2003) Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893–2897

  24. 24.

    Vincenzi B, Santini B, Dicuonzo G et al (2005) Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 25:144–151

  25. 25.

    Bamias A, Kastritis E, Bamia C et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587. https://doi.org/10.1200/JCO.2005.02.8670

  26. 26.

    Cartsos VM, Zhu S, Zavras A (2008) Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714.217 people. Am Dent Assoc 139:23–30

  27. 27.

    Lo JC, O’Ryan FS, Gordon NP et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonates exposure. Oral Maxillofac Surg 68:243–253

  28. 28.

    Felsenberg D (2006) Osteonecrosis of the jaw—a potential adverse effect of bisphosphonate treatment. Nat Clin Pract Endocrinol Metab 2:2662–2663

  29. 29.

    Khan AA et al (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396–1402

  30. 30.

    Lyles KW et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809

  31. 31.

    Powell D, Bowler C, Roberts T et al (2012) Incidence of serious side effects with intravenous bisphosphonates: a clinical audit. QJM 105:965–971

  32. 32.

    Tennis P, Rothman KJ, Bohn RL et al (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21:810–817

  33. 33.

    Grbic JT, Landesberg R, Lin SQ et al (2008) Incidence of osteonecrosis of the jaw in women with postmenosaumal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 139:32–40

  34. 34.

    Devogelaer JP, Brown JP, Burckhardt P et al (2007) Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 18:1211–1218

  35. 35.

    Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia Lymphoma 49(11):2156–2162

  36. 36.

    Klingelhoeffer Ch, Hoffmeister B (2012) Klinische Aspekte der Behandlung von Kiefernekrosen unter antiresorptiver Therapie. Osteologie 3:201–206

  37. 37.

    Ferlito S, Puzzo S, Liardo C (2011) Preventive protocol for tooth extractions in patients treated with zoledronate: a case series. J Oral Maxillofac Surg 69(6):e1–e4

  38. 38.

    Ripamonti CI et al (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145

  39. 39.

    Dimopoulos MA et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120

  40. 40.

    Haidar A et al (2009) Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw. Scand J Urol Nephrol 43:442–444

  41. 41.

    Fehm T, Walter B, Wallwiener D (2010) Bisphosphonatbedingte Kieferosteonekrose. Empfehlungen zur Prävention und Therapie. Gynäkologe 43:517–520

  42. 42.

    Ruggiero SL, Dodson TB, Assael LA et al (2009) Task force on bisphosphonate-related osteonecrosis of the jaws. Am Assoc Oral Maxillofac Surg 69:2–12

  43. 43.

    Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620–623

  44. 44.

    Corso A, Varettoni M, Zappasodi P, Klersy C, Mangiacavalli S, Pica G, Lazzarino M (2007) A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 21:1545

  45. 45.

    Wessel JH, Dodson TB, Zavras AI (2008) Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 66:625–631

  46. 46.

    Chranovic BR, Albrektsson T, Wennerberg A (2015) Smoking and dental implants: a systematic review and meta-analysis. J Dent 43:487–498

  47. 47.

    Shanbhogue VV, Mitchell DM, Rosen CJ et al (2016) Type2 diabetes and the skeleton: new insights into sweet bones. Lancet Diabetes Endocrinol 4:159–173

  48. 48.

    Yahagi K, Kolodgie FD, Lutter C et al (2017) Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arter Thromb Vasc Biol 37:191–204

  49. 49.

    Hua Y, Bi R, Zhang Y et al (2018) Different bone sites-specific response to diabetes rat models: bone density, histology and microarchitecture. PLoS ONE 13:e205503

  50. 50.

    Vahtsevanos K et al (2009) Longitudinal cohortstudy of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362

  51. 51.

    Felsenberg D, Lopez S, Gabbert T, Hoffmeister B (2012) Osteonekrose des Kiefers bei Osteoporosepatienten. Onkologie 3:207–212

  52. 52.

    Felsenberg D, Hoffmeister B, Amling M et al (2006) Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Zahnärztebl 103:3078–3080

  53. 53.

    Shibahara T (2019) Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med 247(2):75–86

  54. 54.

    Vandone AM et al (2012) Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 23:193–200

  55. 55.

    De Iuliis F, Taglieri L, Amoroso L, Vendittozzi S, Blasi L, Salerno G, Lanza R, Scarpa S (2014) Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Anticancer Research 34:2477–2480

  56. 56.

    Bramati A, Girelli S, Farina G, Chiara M et al (2015) Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 33:119–124

Weiterführende Literatur

  1. 57.

    Horn F (2015) Biochemie des Menschen. Thieme, Stuttgart, New York

  2. 58.

    Gilman’s G (2011) The pharmacological basis of therapeutics Bd. 12. Mc Graw Hill Medical, New York, Chicago, San Francisco

  3. 59.

    Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9:177

  4. 60.

    Diel I (2012) Kieferosteonekrosen in der Osteoonkologie. Osteolgie 3:194–200

Download references

Author information

Correspondence to Cand. med. Dent. Niels Karberg BA.

Ethics declarations

Interessenkonflikt

N. Karberg und D. Felsenberg geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Karberg, N., Felsenberg, D. Korreliert die Prävalenz der bisphosphonatassoziierten Kiefernekrosen mit der Einnahmedauer der Bisphosphonate bei Tumor- und Osteoporosepatienten?. J. Miner. Stoffwechs. Muskuloskelet. Erkrank. (2020). https://doi.org/10.1007/s41970-019-00094-6

Download citation

Schlüsselwörter

  • Zahnextraktion
  • Bisphosphonate
  • Zahnmedizin
  • Osteonekrose
  • Bisphosphonatassoziierte Kiefernekrosen (BONJ; ARONJ)

Keywords

  • Toothextraction
  • Bisphosphonates
  • Dentistry
  • Osteonecrosis
  • Bisphosphonate-associated osteonecrosis of the jaw (BONJ; ARONJ)